EVUSHELD 150 mg + 150 mg, solution for injection bottle, 1.5 ml
Active ingredients: CILGAVIMAB, TIXAGÉVIMAB
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionbottle, 1.5 mlintramusculaire
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- EVUSHELD 150 mg + 150 mg, solution injectable
- Pharmaceutical form
- solution injectable et solution injectable
- Route of administration
- intramusculaire
- Presentation description
- 1 flacon(s) en verre de 1,5 ml - 1 flacon(s) en verre de 1,5 ml
- Marketing authorisation holder
- ASTRAZENECA AB
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 22 Dec 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
69232595CIP73025426CIP133400930254264Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CILGAVIMABsolution de cilgavimab | 150 mg · un flacon | SA |
| TIXAGÉVIMABsolution de tixagévimab | 150 mg · un flacon | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.